ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

On location

Researchers Recommend New Processes for Bone Marrow Screening for HLH

For patients suspected of having hemophagocytic lymphohistiocytosis (HLH), bone marrow biopsy is often used to identify the presence of hemophagocytosis and assess for underlying...
On location

e-IRON: Iron-Deficiency Anemia Management at Warp Speed

A telemedicine pilot program to triage and expedite the management of patients with iron-deficiency anemia (IDA) who require intravenous (IV) iron allowed clinicians to...
On location

TPO-RAs and ITP: Eltrombopag Induces High Efficacy, But Avatrombopag Offers Advantages

A pair of studies presented at the 2020 American Society of Hematology Annual Meeting analyzed the thrombopoietin receptor agonist (TPO-RA) eltrombopag in two settings:...
On location

No Difference in CNS Relapse Rate According to Prophylaxis Route

According to results from a retrospective analysis of central nervous system (CNS) prophylaxis in patients with aggressive non-Hodgkin lymphomas (NHLs), rates of CNS relapse...
On location

Researchers Validate Burkitt Lymphoma Prognostic Index

Researchers have created a prognostic index specific to Burkitt lymphoma (BL) that will allow for simplified stratification and comparison of risk distribution in geographically...
On location

Thiotepa-Containing Conditioning Regimens Improve Survival Outcomes in Patients With PCNSL

Thiotepa-containing conditioning regimens, including thiotepa/busulfan/cyclophosphamide (TBC) and thiotepa/carmustine (TT-BCNU), were associated with favorable survival outcomes in patients with primary diffuse large B-cell lymphoma of...
On location

Durable Efficacy With LOXO-305 in Heavily Pretreated CLL/SLL

LOXO-305, a highly selective noncovalent Bruton tyrosine kinase (BTK) inhibitor, was associated with promising response and efficacy rates in patients with heavily pretreated and...
On location

Idecabtagene Vicleucel Promising in Pretreated Myeloma

Three-quarters of patients with heavily pretreated multiple myeloma responded to treatment with the B-cell maturation antigen (BCMA)−targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene...
On location

Evaluating Iberdomide Plus Daratumumab or Bortezomib in Relapsed/Refractory Myeloma

Triplet combinations consisting of iberdomide, a cereblon E3 ligase immunomodulatory drug, with dexamethasone and daratumumab (IberDd) or bortezomib and dexamethasone (IberVd) demonstrated favorable tolerability...
On location

Fostamatinib Improves Hemoglobin Levels in Warm Autoimmune Hemolytic Anemia

Treatment with the oral Syk inhibitor fostamatinib led to “markedly improved” hemoglobin (Hb) levels in patients with warm autoimmune hemolytic anemia (wAIHA), according to...
Advertisement

Current Issue

June 2021 Volume 7 Issue 7

This issue reviews the management and prevention of peripheral neuropathy, early successes of SCD screening programs in sub-Saharan Africa, and more.

Block title